Multidrug-resistant tuberculosis in military recruits

Emerging Infectious Diseases

Volumn 12, Issue 5, 2006, Pages 760-762

  Freier, Grace ^a   Wright, Allen ^a   Nelson, Gregory ^a   Brenner, Eric ^b   Mase, Sundari ^c   Tasker, Sybil ^d   Matthews, Karen L ^d   Bohnker, Bruce K ^e,f  

^a NAVAL HOSPITAL   (United States)

^b SOUTH CAROLINA DEPARTMENT OF HEALTH AND ENVIRONMENTAL CONTROL   (United States)

^c California Department of Health   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e Navy Environmental and Preventive Medicine Unit 2   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN; CLAVULANIC ACID; CLOFAZIMINE; CYCLOSERINE; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN;

ADULT; ARTICLE; CASE REPORT; CONTACT EXAMINATION; DRUG SENSITIVITY; FEMALE; HUMAN; MULTIDRUG RESISTANCE; RECURRENT DISEASE; SOLDIER; TUBERCULOSIS;

EID: 33646585445     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1205.050708     Document Type: Article

References (15)

1. BUMEDINST 6224.8 of 14 Sept 1993. [cited 2005 Mar 03]. Available from http://navymedicine.med.navy.mil/Files/Media/directives/6224-8%20ch-1.pdf
2. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med. 2000;161:1376-95.
3. Centers for Disease Control and Prevention. Targeted tuberculosis testing and treatment of latent tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2000;49:1-54.
4. Centers for Disease Control and Prevention. Management of persons exposed to multidrug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep. 1992;41:59-71.
5. Papastavros T, Dolovich TR, Holbrook A, Whitehead L, Loeb M. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ. 2002;167:131-6.
6. American Thoracic Society; CDC; Infectious Diseases Society of America.. Treatment of tuberculosis. MMWR Recomm Rep. 2003;52(RR-11):1-77.
7. Passannante MR, Gallagher CT, Reichman LB. Preventive therapy for contacts of multidrug-resistant tuberculosis. A Delphi survey. Chest. 1994;106:431-4.
8. Horn DL, Hewlett D, Alfalla C, Peterson S, Opal SM. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis. N Engl J Med. 1994;330:1241.
9. Ridzon R, Meador J, Maxwell R, Higgins K, Weismuller P, Onorato I. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Clin Infect Dis. 1997;24:1264-5.
10. Bloomberg HM, Leonard MK, Jasmer RM. Update on the treatment of tuberculosis and latent tuberculosis. JAMA. 2005;293:2766-84. Erratum in: JAMA. 2005;294:18.
11. Alvirez-Freites EJ, Carter JL, Cynamon HL. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2002;46:1022-5.
12. Aubry A, Pan XS, Fisher LM, Jarlier V, Cambau E. Mycobacterium tuberculosis DNAgyrase: interaction with quinolones and correlation with anti-mycobacterial drug activity. Antimicrob Agents Chemother. 2004;48:1281-8.
13. Gamble-Lawson C, Bowman C, Suesz W, Riegodedios A, Bohnker BK. Tuberculosis in the US Navy and Marine Corps: a 4 year retrospective analysis (2000-2003). Navy Medical Surveillance Report. 2004. [cited 2005 Nov 7]. Available from http://wwwnehc. med.navy.mil/downloads/prevmed/NMSROctDec04.pdf
14. Centers for Disease Control and Prevention (CDC). Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep. 2005;54:1-81
15. Centers for Disease Control and Prevention (CDC). Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Morb Mortal Wkly Rep. 2005;54:1-37